Water Island Capital LLC Lowers Position in Catalent, Inc. (NYSE:CTLT)

Water Island Capital LLC decreased its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 16.6% during the second quarter, according to its most recent filing with the SEC. The firm owned 537,856 shares of the company’s stock after selling 107,004 shares during the period. Catalent accounts for about 3.2% of Water Island Capital LLC’s portfolio, making the stock its 16th largest position. Water Island Capital LLC owned 0.30% of Catalent worth $30,244,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CTLT. Nisa Investment Advisors LLC lifted its stake in shares of Catalent by 1.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after purchasing an additional 185 shares during the last quarter. Lindbrook Capital LLC lifted its position in shares of Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares in the last quarter. Czech National Bank grew its position in shares of Catalent by 0.7% in the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after buying an additional 228 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in shares of Catalent by 1.4% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock worth $1,082,000 after acquiring an additional 257 shares in the last quarter.

Insider Buying and Selling

In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the sale, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the transaction, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Insiders sold a total of 15,403 shares of company stock valued at $902,503 over the last 90 days. Insiders own 0.31% of the company’s stock.

Catalent Stock Up 0.1 %

Shares of CTLT stock opened at $60.33 on Monday. Catalent, Inc. has a fifty-two week low of $31.80 and a fifty-two week high of $61.20. The firm has a market capitalization of $10.92 billion, a PE ratio of -9.89, a P/E/G ratio of 2.32 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The stock’s 50-day simple moving average is $59.69 and its 200-day simple moving average is $57.34.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. Equities analysts expect that Catalent, Inc. will post 0.85 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have weighed in on CTLT. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird restated a “neutral” rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Barclays boosted their price target on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. Finally, StockNews.com assumed coverage on shares of Catalent in a research report on Thursday. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. According to MarketBeat.com, Catalent presently has an average rating of “Hold” and an average target price of $59.83.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.